Research & Development

Ovid signs license deal with AstraZeneca to expand epilepsy drug pipeline

Ovid Therapeutics has signed a license agreement with AstraZeneca for a library of early-stage small molecules that target the KCC2 transporter.

Ascletis expands ritonavir oral tablets production amid Covid-19 surge

Ascletis Pharma is expanding the production of ritonavir oral tablets as well as the oral direct-acting antiviral R&D pipeline to treat SARS-CoV-2 virus amid the recent surge in Covid-19 cases.

BSF Enterprise to acquire 3D Bio-Tissues

BSF Enterprise has signed a conditional agreement to acquire 3D Bio-Tissues (3DBT) in a deal worth $3.34m (£2.5m).

Ambys raises funding to expand liver cell therapy production capabilities

Ambys Medicines has secured $47m Series A financing extension for the continued expansion of its production capabilities of liver cell therapy.

Alpine Immune, Horizon enter autoimmune disease research collaboration

Alpine Immune Sciences and Horizon Therapeutics have signed an exclusive licence and collaboration agreement to develop protein-based therapies to treat autoimmune and inflammatory diseases.

Bristol Myers Squibb signs deal with Immatics for solid tumour drug

Bristol Myers Squibb has signed a license, development, and commercialisation agreement with clinical-stage biopharmaceutical firm Immatics for the latter's TCR Bispecific candidate for solid tumours, IMA401.

Arbutus discovers molecular targets to treat Covid-19

Canadian biopharmaceutical firm Arbutus Biopharma has identified many molecules that can inhibit the SARS-CoV-2 nsp5 main protease (Mpro), achieving its first milestone under Covid-19 discovery research and license deal.

Quell raises $156m Series B funds to develop cell therapies

Quell Therapeutics has raised $156m funding through an oversubscribed Series B funding round to advance its multi-modular engineered T regulatory (Treg) cell therapy pipeline and platform.

Novo Nordisk to buy Dicerna to expand RNAi technology use

Danish pharma company Novo Nordisk has agreed to acquire Dicerna Pharmaceuticals and its ribonucleic acid interference (RNAi) platform in a deal valued at $3.3bn, to expand the RNAi technology use.